Announcement Date for 2022 Half Year Results
Dublin, 25 August 2022: HealthBeacon plc ("HealthBeacon" or the "Company") and together with its subsidiary undertakings (together the "Group"), the leading Irish digital therapeutics company, will release Half Year Results for the six months to 30 June 2022, on Friday, 30 September 2022.
The Company's Half Year Results Announcement and recorded Presentation will be available on the HealthBeacon website (www.HealthBeacon.com) at 07.00am on 30 September 2022.
| For further details contact: |
|
| HealthBeacon: Laurence Flavin
|
Investor.Relations@HealthBeacon.com |
| Goodbody (Euronext Growth Sponsor and Broker): David Kearney |
+353 (1) 667 0420 |
| Stephen Kane |
|
|
Drury (Public Relations): |
|
| Cathal Barry Paul Clifford |
+353 (0) 87 227 9281 +353 (0) 87 327 2161 |
About HealthBeacon
Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops products for managing injectable medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company's mission is to become the world's leading digital therapeutics platform for injectable medications.
Ends
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.